EQT Life Sciences has successfully completed a Series B extension investment round in Noema Pharma, raising a total of CHF 130 million to support the development of innovative therapies for central nervous system disorders.

Information on the Target

Noema Pharma, a clinical-stage biotechnology company based in Basel, Switzerland, specializes in developing innovative therapies for debilitating central nervous system (CNS) disorders. Founded in 2019 with initial funding from Sofinnova Partners, Noema Pharma is currently advancing a portfolio of first-in-disease therapeutics designed to address significant unmet medical needs in neuroscience. The company is conducting four active Phase 2 clinical trials, which are pivotal in testing their innovative drug candidates.

The recent Series B extension financing round, amounting to CHF 130 million (approximately USD 147 million), is led by EQT Life Sciences, which joins a strong syndicate of existing investors including Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris Partners, Invus, and UPMC Enterprises. This capital infusion will enable Noema Pharma to advance its clinical programs and move closer to achieving key data readouts expected in 2025.

Industry Overview in Switzerland

Switzerland is known for its robust life sciences sector, characterized by a combination of established pharmaceutical companies, innovative biotech firms, and extensive research institutions. The country benefits from a well-structured regulatory environment